Human muscle in gene edited pigs for treatment of volumetric muscle loss

Sarah M. Greising, Joshua I. Weiner, Daniel J. Garry, David H. Sachs, Mary G. Garry

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Focusing on complex extremity trauma and volumetric muscle loss (VML) injuries, this review highlights: 1) the current pathophysiologic limitations of the injury sequela; 2) the gene editing strategy of the pig as a model that provides a novel treatment approach; 3) the notion that human skeletal muscle derived from gene edited, humanized pigs provides a groundbreaking treatment option; and 4) the impact of this technologic platform and how it will advance to far more multifaceted applications. This review seeks to shed insights on a novel treatment option using gene edited pigs as a platform which is necessary to overcome the clinical challenges and limitations in the field.

Original languageEnglish (US)
Article number948496
JournalFrontiers in Genetics
Volume13
DOIs
StatePublished - Jul 25 2022

Bibliographical note

Funding Information:
Grant funding from the Department of Defense (OR180095 and 12975188) to MG; Department of Defense 12974858) to DG; Department of Defense (12975087) to DS. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense.

Publisher Copyright:
Copyright © 2022 Greising, Weiner, Garry, Sachs and Garry.

Keywords

  • blastocyst complementation
  • human animal chimeras
  • skeletal muscle function
  • somatic cell nuclear transfer
  • xenotransplantation

PubMed: MeSH publication types

  • Journal Article
  • Review

Fingerprint

Dive into the research topics of 'Human muscle in gene edited pigs for treatment of volumetric muscle loss'. Together they form a unique fingerprint.

Cite this